UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number: 001-35068 ACELRX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 41-2193603 (State or other jurisdictio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35068 ACELRX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organi ...

AcelRx Pharmaceuticals, Inc. (ACRX) Q4 2019 Results Earnings Conference Call March 16, 2020 8:30 AM ET Company Participants Raffi Asadorian - CFO Vince Angotti - CEO Pamela Palmer - Chief Medical Officer and Co-Founder Koth Cassavaugh - Director of Pharmacy, Auburn Community Hospital Conference Call Participants Brandon Folkes - Cantor Fitzgerald Chris Howerton - Jefferies Ed Arce - H.C. Wainwright Michael Higgins - Ladenburg Thalmann Operator Good day, and welcome to the AcelRx's Fiyrtg Quarter 2019 and Te ...

AcelRx Pharmaceuticals, Inc. (ACRX) Q3 2019 Earnings Conference Call November 6, 2019 5:00 PM ET Company Participants Raffi Asadorian - CFO Vince Angotti - CEO Pam Palmer - Chief Medical Officer and Co-Founder Charles Lee - Board Certified Plastic and Reconstructive Surgeon Conference Call Participants Ed Arce - H.C. Wainwright Syed Kareem - Jefferies Michael Higgins - Ladenburg Thalmann Operator Good day, and welcome to the AcelRx's Third Quarter 2019 Conference Call. This call is being webcast live on the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number: 001-35068 ACELRX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 41-2193603 (State or other jurisdi ...

AcelRx Pharmaceuticals, Inc. (ACRX) Q 2, 2019 Earnings Conference Call August 5, 2019 5:00 PM ET CompanyParticipants Vince Angotti - Chief Executive Officer Raffi Asadorian - Chief Financial Officer Pam Palmer - Chief Medical Officer and Co-Founder Jacob Hutchins - Anesthesiologist and Associate Professor, Department of Anesthesiology Conference CallParticipants Brandon Folkes - Cantor Fitzgerald Randall Stanicky - RBC Capital Markets Ed Arce - H.C. Wainwright Chris Howerton - Jefferies Andrew D'Silva - B R ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number: 001-35068 ACELRX PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 41-2193603 (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2019 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number: 001-35068 (Exact name of registrant as specified in its charter) Delaware 41-2193603 (State or other jurisdiction of incorporation or organiz ...

AcelRx Pharmaceuticals, Inc. (ACRX) Q1 2019 Earnings Conference Call May 8, 2019 4:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vince Angotti - Chief Executive Officer Pam Palmer - Chief Medical Officer Conference Call Participants Dan Busby - RBC Capital Markets Brandon Folkes - Cantor Fitzgerald Vamil Divan - Credit Suisse Michael Higgins - Ladenburg Thalman Andrew D'Silva - B Riley FBR Aryeh Gold - Oppenheimer Operator Welcome to the AcelRx First Quarter 2019 Conference Call. T ...

| --- | --- | |---------------------------------------|--------------------| | | | | | | | | | | | | | Oppenheimer 29 th Annual Healthcare | | | Conference | | | March 20, 2019 | | | | | | Investor materials | MED-US-DSU-1900037 | Cautionary statements 2 This presentation contains forward-looking statements, including, but not limited to, statements related to the safety, efficacy and therapeutic value of DSUVIA™ (sufentanil sublingual tablet, 30 mcg) and ZALVISO® (the sufentanil sublingual tablet system); ...